e-learning
resources
Berlin 2008
Monday, 06.10.2008
Pulmonary vascular medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Polymorphism of the serotonin transporter and 2a receptor gene in COPD with and without pulmonary hypertension
S. Ulrich, M. Fischler, M. Hersberger, U. Treder, E. W. Russi, R. Speich (Zurich, Switzerland)
Source:
Annual Congress 2008 - Pulmonary vascular medicine
Session:
Pulmonary vascular medicine
Session type:
Oral Presentation
Number:
1584
Disease area:
Airway diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Ulrich, M. Fischler, M. Hersberger, U. Treder, E. W. Russi, R. Speich (Zurich, Switzerland). Polymorphism of the serotonin transporter and 2a receptor gene in COPD with and without pulmonary hypertension. Eur Respir J 2008; 32: Suppl. 52, 1584
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive lung disease
Source: Eur Respir J 2003; 22: Suppl. 45, 20s
Year: 2003
Estrogen receptor alpha gene polymorphisms and primary pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 352s
Year: 2005
Overexpression of serotonin receptor 1B (5HT-1B) responsible for overflow induced experimental pulmonary arterial hypertension development
Source: Annual Congress 2003 - Pathophysiology of the pulmonary circulation
Year: 2003
Mice over-expressing the 5-HT transporter gene develop pulmonary hypertension
Source: Annual Congress 2004 - Pathophysiology of pulmonary hypertension
Year: 2004
Effect of dexfenfluramine on the development of pulmonary hypertension in mice over-expressing the serotonin transporter
Source: Eur Respir J 2005; 26: Suppl. 49, 352s
Year: 2005
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Pulmonary hypertension in COPD
Source: Eur Respir Mon 2013; 59: 189-205
Year: 2013
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
Single centre experience with endothelin receptor blockade in pulmonary hypertension
Source: Annual Congress 2004 - Pulmonary hypertension
Year: 2004
Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2006 - Cellular mechanisms of airway disease
Year: 2006
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation
Source: Eur Respir J 2003; 22: 560-562
Year: 2003
Dual endothelin receptor antagonism: setting standards in PAH
Source: Eur Respir Rev 2008; 17: 13-18
Year: 2007
Expression of the serotonin 1b receptor in experimental pulmonary hypertension
Source: Eur Respir J 2003; 22: 408-412
Year: 2003
Interleukin-1b and interleukin-1 receptor antagonist gene polymorphisms in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: Suppl. 48, 136s
Year: 2004
Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 271s
Year: 2003
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018
Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Endothelin receptor antagonists in pulmonary arterial hypertension
Source: Eur Respir J 2008; 31: 407-415
Year: 2008
Relationship between Galectin-3 and mineralocorticoid receptor in pulmonary hypertension
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept